MRI measures should be a primary outcome endpoint in phase III randomised controlled trials in multiple sclerosis: Commentary

Abstract

Get full access to this article

View all access options for this article.

References

Portaccio

Stromillo

Goretti

. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. Neurology 2009; 73: 498–503.

Goldman

Motl

Scagnelli

. Clinically meaningful performance benchmarks in MS: Timed 25-Foot Walk and the real world. Neurology 2013; 81: 1856–1863.

Langdon

Amato

Boringa

. Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler 2012; 18: 891–898.

Cadavid

Wolansky

Skurnick

. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009; 72: 1976–1983.

Bagnato

Jeffries

Richert

. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 2003; 126: 1782–1789.

Lumsden

. In: Vinken

Bruyn

(eds) Handbook of Clinical Neurology. Vol 9. Amsterdam: North Holland, 1970, pp.217–309.

Scalfari

Neuhaus

Degenhardt

. The natural history of multiple sclerosis: A geographically based study 10: Relapses and long-term disability. Brain 2010; 133: 1914–1929.

Confavreux

Vukusic

. Natural history of multiple sclerosis: A unifying concept. Brain 2006; 129: 606–616.

Leray

Yaouanq

Le Page

. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133: 1900–1913.

10.

Fisniku

Brex

Altmann

. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808–817.

11.

Lublin

Baier

Cutter

. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61: 1528–1532.